valid model pt
volum new high term unit growth beat
guidanc impli acceler margin outlook
pressur capac expans commerci invest
expect one time pt remain
let stay focus big pictur deliv strongest quarter
histori compani volum ebit stock
trade price-to-earnings in-lin earn growth
trajectori support investor feedback post result indic
degre disappoint lack leverag embed
outlook would call weak stock buy opportun given
sourc pressur margin product capac expans
drive longer term freight cost lower margin higher turnaround time
faster promot spend compani quickli translat
faster organ growth last two year close book
demonstr capac innov faster commerci strategi
new product intern expans drive acceler growth even
manag focus new initi moat rel potenti
competitor ever wider compani abil convert ortho market
align increasingli undeni rais pt pt remain
base dcf bull case goe higher
tough setup print expect algn high
strong perform posit checks/feedback intra-quart kept
equiti market bid growth stori indirectli taken expect higher
drive materi disconnect even optimist investor view
fundament multipl stock pt rais
reflect optim core busi view new
innov drive growth faster particularli among
chang view price target base result outlook
stock howev date within target price
make difficult forecast stronger near term stock perform advanc
updat new product launch expert feedback clariti
product featur compet align system come year align
survey support growth expect high barrier entri
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
exhibit case volum growth acceler new high growth
learn quarter outlook observ
organ growth acceler guidanc call
suggest growth rang achiev work suggest
trend acceler quarter ebit may see leverag though
fx volum growth drive upsid histor outperform
conserv margin guidanc visibl low chang cog
line tie new treatment center capac prove one-tim teen growth
remain rang look sustain categori much
like intern grow term mix support overal growth
sign thu far blowback scan receipt polici chang
mandibular advanc us launch assum model least
quarter away fda work evalu new categori technolog
walk updat estim rais revenu
forecast fx drive higher momentum continu
elev teen/dtc intern commerci push exhibit
ep forecast goe arguabl conserv
assum flat ebit margin year fx appear like tailwind
seen benefit year estim contempl
competit ramp low-end market next year
like counter via new product invisalign go
maintain pt base revis long-term dcf impli
price-to-earnings multipl discount current multipl ntm price-to-earnings
ep compound-annual-growth-rate
strong market augment distribut major competitor emerg
macro trend improv expect us europ at-hom
align market grow fast predic aesthet market key
beneficiari share
underli trend improv top-line growth moder
tough comp align abl retain key share among high-volum
ortho north america increas digit
intern sale continu grow clip medium term ep
growth compound-annual-growth-rate captur emerg at-hom align
opportun
competit littl tougher macro environ slow
aggress promot competit product activ us europ
us high-end spend growth stabil recoveri post-crisi
investor turn attent ip expir npv impact
addit competit at-hom align opportun emerg slowli
captur share
invisalign growth expect continu
assum increment competit despit
potenti entrant near term
new featur market support
differenti barrier entri
consum sensit remain high
invisalign typic target toward case
discretionari
interoper intraor scanner
includ siro omnicam expand
potenti custom base
appear like key beneficiari
emerg at-hom align opportun
could size core
invisalign consum appeal substanti
clear align far less disrupt
patient activ tradit brace
align offer wide array featur set
orient vari degre physician
profici patient age case sever
increas mix digit case submiss
current orthodont total
time half
inflect discretionari spend
local facil salesforc emea
apac
risk achiev price
spend us abroad
new competit entri aggress
price
loss tax deduct
exhibit revenu growth rel profit growth
exhibit chang forecast
sale
sale
sale
sale
sale
sale
compani data morgan stanley research
valuat risk
exhibit ev/sal valuat vs fast growth compani
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
price target impli price-to-earnings ep base dcf
analysi valuat methodolog take long-term view busi
believ present signific upsid captur compani revenu cost growth
outlook discount wacc termin growth rate
see acceler ep growth ep compound-annual-growth-rate
rang busi reap benefit agreement sdc increas
digit technolog among dentist intern market penetr
risk price target includ discretionari consum spend trend
competit entri market
million us dollar
 increas work capit
million us dollar
pv free flow
pv termin valu
pv tax benefit
bv equiti invest
base capit
equiti
margin debt
after-tax debt
deceler revenu growth
depreci revenu
work capit revenu
capital-expenditure revenu
compani data morgan stanley research
compani data morgan stanley research
compani data morgan stanley research
